Bookmark and Share
SMR000163731 (CID 1733268) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(12)
 
 
Inactive(699)
 
 
Inconclusive(13)
 
 
Unspecified(3)
 
 
Top Targets:
7TM GPCR Srx(18)
 
 
7TM GPCR Srsx(16)
 
 
alkPPc(14)
 
 
Lactamase B(13)
 
 
 
Bcl-2 like(11)
 
 
BioAssay Types:
Screening(484)
 
 
 
 
 
Confirmatory(207)
 
 
 
 
 
Literature(11)
 
 
BioActivity Types:
Potency(147)
 
 
 
 
 
IC50(46)
 
 
 
EC50(7)
 
 
Ki(1)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 656    Data Row: 727   Total Pages: 37   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID135631809]
Ki 1.781Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit VIM-2 [AID624083, Type: confirmatory]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
2
[SID124360376]
MIC [4 fold reduction] 3.125Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
3
[SID124384965]
IC50 3.98Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit VIM-2 [AID624079, Type: confirmatory]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
4
[SID135631809]
IC50 4.55Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit VIM-2 [AID624079, Type: confirmatory]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
5
[SID124384965]
MIC [4 fold reduction] 6.25Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): VIM-2-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624081, Type: other]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
6
[SID124384965]
MIC [4 fold reduction] 6.25Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
7
[SID17401254]
Potency 56.2341qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a [AID504332, Type: confirmatory]euchromatic histone-lysine N-methyltransferase 2 [Homo sapiens] [gi:168985070]
View
8
[SID17401254]
Cytochrome panel assay with activity outcomes [AID1851_3, Type: other]cytochrome P450 3A4 isoform 1 [Homo sapiens] [gi:13435386]
View
9
[SID17401254]
Primary cell-based high throughput screening assay to measure STAT3 activation [AID871, Type: screening]STAT3 [Homo sapiens] [gi:13272532]
View
10
[SID17401254]
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1) [AID652257, Type: screening]PRMT1 protein [Homo sapiens] [gi:32425330]
View
11
[SID17401254]
Cytochrome panel assay with activity outcomes [AID1851_1, Type: other]cytochrome P450 2C19 precursor [Homo sapiens] [gi:4503219]
View
12
[SID17401254]
CYP2C9 Assay [AID777, Type: screening]cytochrome P450 2C9 precursor [Homo sapiens] [gi:13699818]
View
13
[SID17401254]
Cytochrome panel assay with activity outcomes [AID1851, Type: other]
View
14
[SID17401254]
Potency qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate [AID624178, Type: confirmatory]acid sphingomyelinase [Homo sapiens] [gi:179095]
View
15
[SID17401254]
Assay for HTS of Gi/Go-linked GPCRs using mGluR8: Primary Screening [AID488969, Type: screening]metabotropic glutamate receptor 8 [Rattus norvegicus] [gi:1575471]
View
16
[SID17401254]
Potency 1.1689Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation [AID504834, Type: confirmatory]
View
17
[SID17401254]
Potency 10qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen [AID720542, Type: confirmatory]apical membrane antigen 1, AMA1 [Plasmodium falciparum 3D7] [gi:23496270]
View
18
[SID17401254]
Potency 10.4179Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation [AID504832, Type: confirmatory]
View
19
[SID124384965]
MIC [4 fold reduction] 25Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624097, Type: other]metallo-beta-lactamase IMP-1 [Pseudomonas aeruginosa] [gi:27368096]
View
20
[SID124384965]
IC50 31.9Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit IMP-1 [AID624085, Type: confirmatory]metallo-beta-lactamase IMP-1 [Pseudomonas aeruginosa] [gi:27368096]
View